公开(公告)号：US20230235355A1

公开(公告)日：2023-07-27

申请号：US18000815

申请日：2021-06-05

Applicant: EpicentRx, Inc.

Inventor： Tony R. REID ,  Bryan T. ORONSKY

IPC: C12N15/86 ,  C07K14/165 ,  A61K9/00 ,  C07K16/10 ,  A61K39/12 ,  A61P31/14 ,  A61P35/00

CPC classification number: C12N15/86 ,  C07K14/165 ,  A61K9/0019 ,  C07K16/10 ,  A61K39/12 ,  A61P31/14 ,  A61P35/00 ,  A61K2039/5256

Abstract: The present disclosure relates to recombinant human adenoviruses engineered to express a structural protein of a coronavirus. The recombinant adenoviruses are suitable for active immunization against a coronavirus in a human subject. Additionally, immune globulin obtained from immunized human subjects is suitable for passive immunization of a coronavirus-infected human subject.

公开(公告)号：US20220125946A1

公开(公告)日：2022-04-28

申请号：US17575488

申请日：2022-01-13

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.